Enhancing Micronization Processes With SYLOID® Mesoporous Silica

Micronization — the process of reducing the particle size of active pharmaceutical ingredients (APIs) — plays a pivotal role in improving dissolution rates and bioavailability. This step is especially critical for APIs that demand fine and uniform particles to ensure consistent drug loading and optimal performance in oral solid dosage forms. Yet, traditional jet milling methods, while effective for particle reduction, frequently introduce complications such as poor powder flow, particle agglomeration, and static charge buildup, all of which can disrupt downstream processing and manufacturing efficiency.

In response to these challenges, we pursued an innovative approach using mesoporous silica as a means to enhance the micronization process. Partnering with Microsize, North America’s largest independent pharmaceutical micronization company, Grace conducted a series of controlled studies to evaluate how incorporating SYLOID® mesoporous silica could alleviate these issues and deliver measurable improvements in process performance and material handling.

Discover how this advancement is redefining the path to more efficient and reliable API formulation.